Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bates

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
BJU International|May 8, 2024
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC MonitorMaximilian Haas, Maximilian C Kriegmair, Johannes Breyer, et al.
Cancer Research|February 18, 2011
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimersRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, et al.
Scientific Reports|September 18, 2023
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)Johannes Breyer, Markus Eckstein, Danijel Sikic, et al.
Breast Cancer Research and Treatment|August 19, 2018
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platformNatalie C Wu, Wendy Wong, Kenneth E Ho, et al.
Breast (Edinburgh, Scotland)|November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective TrialKala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2023
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction CancerAileen I Fernandez, Charles J Robbins, Patricia Gaule, et al.
Pathology Research International|December 15, 2010
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor SpecimensJeffrey S Larson, Laurie J Goodman, Yuping Tan, et al.
Cancer Research Communications|September 1, 2022
Development of an automated liquid biopsy assay for methylated markers in advanced breast cancerMary Jo Fackler, Suzana Tulac, Neesha Venkatesan, et al.
BJU International|April 1, 2021
Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert<sup>®</sup> Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancerBarrett Cowan, Eric Klein, Ken Jansz, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
BJU International|May 8, 2024
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC MonitorMaximilian Haas, Maximilian C Kriegmair, Johannes Breyer, et al.
Cancer Research|February 18, 2011
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimersRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, et al.
Scientific Reports|September 18, 2023
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)Johannes Breyer, Markus Eckstein, Danijel Sikic, et al.
Breast Cancer Research and Treatment|August 19, 2018
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platformNatalie C Wu, Wendy Wong, Kenneth E Ho, et al.
Breast (Edinburgh, Scotland)|November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective TrialKala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2023
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction CancerAileen I Fernandez, Charles J Robbins, Patricia Gaule, et al.
Pathology Research International|December 15, 2010
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor SpecimensJeffrey S Larson, Laurie J Goodman, Yuping Tan, et al.
Cancer Research Communications|September 1, 2022
Development of an automated liquid biopsy assay for methylated markers in advanced breast cancerMary Jo Fackler, Suzana Tulac, Neesha Venkatesan, et al.
BJU International|April 1, 2021
Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert<sup>®</sup> Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancerBarrett Cowan, Eric Klein, Ken Jansz, et al.
Pageof 8